AIHTA - Announcements

©AIHTA

Uptake of Mental Health Benefits in Women Before and During the Perinatal Period: An Analysis of Austrian Health Insurance Data

On average, one in five women suffer from a mental illness during the perinatal period (pregnancy up to 1 year after birth. So far, it has been unknown how many women claim mental health services during this period. The analysis of pseudonymised insurance data revealed that around 20% of women in Austria who gave birth in 2017 and 2018 used at least one of five examined mental health services during the perinatal period. However, very few specialised perinatal mental health services are available in Austria, with regional disparities. The quality of existing services should be evaluated, and gaps in care need to be closed.

Publication: HTA Project Report No. 154: https://eprints.aihta.at/1535/
Contact: Ingrid Zechmeister-Koss

More...

©stock.adobe.com

Horizon Scanning in Oncology - Fact Sheets

We are pleased to introduce you four new Fact Sheets.

Fact Sheet No. 180 (June 2024)
Erdafitinib (Balversa®) as monotherapy for the treatment of unresectable or metastatic urothelial carcinoma (UC)

Fact Sheet No. 181 (June 2024)
Odronextamab (Ordspono®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (r/r FL) or diffuse large B?cell lymphoma (r/r DLBCL)

Fact Sheet No. 182 (June 2024)
Durvalumab (Imfinzi®) in combination with carboplatin and paclitaxel for the first-line treatment of primary advanced or recurrent endometrial cancer (EC), followed by maintenance treatment durvalumab (Imfinzi®) as monotherapy in EC that is mismatch repair deficient (dMMR) or in combination with olaparib (Lynparza®) in EC that is mismatch repair proficient (pMMR)

Fact Sheet No. 183 (June 2024)
Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL)

More...

©stock.adobe.com

Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer

This update report assesses three alternative treatments to radical therapies for localised prostate cancer (PCA): irreversible electroporation (IRE) uses electrode needles to target and destroy carcinoma tissue; stereotactic radiation therapy (SBRT) and proton therapy (PT) are forms of external beam radiation therapy, SBRT delivers high dose radiation in fewer fractions than conventional or moderate fractionation radiation, while PT delivers high-dose ionizing radiation with great precision.

The current evidence remains insufficient to conclude that IRE, SBRT, and PT improve outcomes in terms of survival and quality of life, as well as the avoidance of radical invasive procedures like prostatectomy, compared to conventional therapies. Recent RCTs on SBRT show minor differences in survival rates compared to conventional fractionation radiation in low- and intermediate-risk PCa. Further research is necessary for definitive conclusions.

Publication: Project Report No.: 107/1. Update: https://eprints.aihta.at/1530/
Contact: Judit Erdös

More...

©stock.adobe.com

Evaluation of individual medical procedures - Reports 2024

We are pleased to introduce our new reports.

Decision Support Documents 2024:

DSD 139: Caval valve implantation for severe tricuspid regurgitation https://eprints.aihta.at/1525
DSD 140: Electroconvulsive therapy in treatment-resistant depression and treatment-resistant schizophrenia https://eprints.aihta.at/1526
DSD 141: Thermoablation for benign thyroid nodules https://eprints.aihta.at/1527

+ 2 Updates

DSD 24: Percutaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB) in patients with coronary artery disease (CAD). 3. Update 2024 https://eprints.aihta.at/1528
DSD 45: Renal denervation (RDN) in patients with treatment resistant hypertension. 2. Update 2024 https://eprints.aihta.at/1529

More...

©stock.adobe.com

Point of Care Tests (POCT): D-Dimer and Troponin. Update 2024

Point of care tests (POCTs) for troponin (Tn) and D-Dimer enable rapid diagnostics near patients. Tn-POCTs are used when there is a suspicion of acute coronary syndrome (ACS) and D-Dimer-POCTs are used when there is a suspicion of venous thromboembolism (VTE).

The aim of this report is to evaluate the clinical utility of the two POC diagnostics, D-Dimer and troponin, in primary care.

Publication: HTA Project Report No. 124, 1. Update 2024: https://eprints.aihta.at/1524/
Contact: Claudia Wild

More...